The FDA decision on approving the expanded use of Dupixent as a treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis is expected on March 11, 2019.Developed by Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY), Dupixent was approved in the U.S. in March 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose condition is not properly controlled with topical therapies, and in October 2018 for moderate-to-severe asthma.The annual net product sales of Dupixent recorded by Sanofi were $922 million in 2018 compared to $256 million in 2017. REGN closed Tuesday’s trading at $426.15, up 1.37%.